Science Resources
Earth Science
Space Science
Life Science
Fields of Scientific Study
Medical Topics and Fields
Cancer Research
Nanotechnology Articles
RSS Feeds
|
 |
 |
 |
HIV-1 protease inhibitor induced oxidative stress in pancreatic B-cells: thymoquinone protection
March 26, 2009
Researchers at the Tulane University School of Medicine, New Orleans, Louisiana have discovered that the HIV-1 protease inhibitors (PIs), such as nelfinavir included in highly active antiretroviral therapy (HAART) regimen for the treatment of HIV-1 patients, induce deleterious effects on insulin secretion mediated through the oxidative stress pathway. They report a significant decrease in the levels of the antioxidants, cytosolic superoxide dismutase (Cu/Zn SOD) and glutathione, whereas mitochondrial SOD levels remained unaffected in pancreatic beta-cells (INS-1 cells) exposed to nelfinavir. However, the mitochondrial uncoupling protein (UCP2) levels were up-regulated during nelfinavir induced oxidative stress and directly affected the ATP levels in these cells. A significant decrease in ATP production was also observed which may account for the decrease in glucose stimulated insulin secretion upon nelfinavir treatment. This study appears in the April 2009 issue of Experimental Biology and Medicine. Although insulin resistance has been clinically observed in HIV-1 patients receiving HAART regimen, the molecular mechanisms of this metabolic abnormality have not been delineated. The research team led by Dr. Krishna C. Agrawal, Regents Professor and Chairman included Surabhi Chandra, a graduate student and another faculty member, Dr. Debasis Mondal in the Department of Pharmacology. These investigators successfully tested the hypothesis that nelfinavir induced oxidative stress was responsible for the deleterious effects of the HIV-1 protease inhibitor on insulin production by pancreatic beta-cells and they further investigated the therapeutic strategies to ameliorate the insulin dysregulation at this level. Since the hypoglycemic effects of Nigella sativa oil have been investigated in the past, the investigators postulated that nelfinavir induced oxidative stress may be ameliorated by the administration of the active ingredient of this oil, thymoquinone. Furthermore, it was envisioned that since thymoquinone shares a structural homology with ubiquinone (mitochondrial component) it is likely that it may act as a mitochondrial antioxidant. Indeed pretreatment of pancreatic beta-cells with thymoquinone caused a reversal of nelfinavir induced deleterious effects. Thymoquinone decreased the production of reactive oxygen species, increased the Cu/Zn SOD and glutathione levels, suppressed the UCP-2 protein levels and restored nelfinavir induced decrease in insulin secretion to normal levels in these cells. Dr. Agrawal commented, "An important finding of this study is that the dysregulation of insulin production in pancreatic beta-cells is due to generation of reactive oxygen species induced by nelfinavir, an HIV-1 protease inhibitor". Furthermore, Dr. Agrawal said, "thymoquinone, an antioxidant provided a significant protection to pancreatic beta-cells from the toxic effects of nelfinavir and therefore these findings clearly suggest a potential role for the use of black seed oil or thymoquione as a protective agent against HIV-1 protease inhibitor induced deleterious effects on pancreatic beta-cells".
Society for Experimental Biology and Medicine
|
 |
Related Protease Inhibitor Current Events and Protease Inhibitor News Articles Protease Inhibitor Current Events and Protease Inhibitor News RSS Researchers restore missing protein in rare genetic brain disorder UCSF researchers have successfully used protease inhibitors to restore to normal levels a key protein involved in early brain development. Reduced levels of that protein have been shown to cause the rare brain disorder lissencephaly, which is characterized by brain malformations, seizures, severe mental retardation and very early death in human infants.
HIV integrase inhibitor effective for patients beginning antiretroviral treatment A member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV, according to researchers who have completed a two-year multisite phase III clinical trial comparing it with standard antiretroviral drugs.
NEJM Study Points to New Era in Hepatitis C Treatment For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.
New information points to safer methadone use for treatment of pain and addiction New findings may significantly improve the safety of methadone, a drug widely used to treat cancer pain and addiction to heroin and other opioid drugs, according to researchers at Washington University School of Medicine in St. Louis and the University of Washington in Seattle.
Arterial infusion using gabexate mesilate: Is it effective therapy for severe acute pancreatitis? Severe acute pancreatitis (SAP) remains a lethal disease. It is defined as an inflammatory process of the pancreas with possible peripancreatic tissue and multi-organ involvement inducing multi-organ dysfunction syndrome (MODS) with an increased mortality rate.
Arterial infusion using gabexate mesilate: Is it effective therapy for severe acute pancreatitis? Severe acute pancreatitis (SAP) remains a lethal disease. It is defined as an inflammatory process of the pancreas with possible peripancreatic tissue and multi-organ involvement inducing multi-organ dysfunction syndrome (MODS) with an increased mortality rate.
Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.
An effective method to study the pressure of the Sphincter of Oddi The Sphincter of Oddi (SO) plays a vital role in maintaining the normal bile duct pressure, promoting gallbladder excretion and preventing from reflux.
ABC-transporters expressed on endothelial cell membranes efflux anti-HIV drugs Researchers at Tulane University Medical Center in New Orleans (USA) have discovered that drug-efflux pumps, belonging to the ATP-binding cassette (ABC) transporter family, are constitutively expressed on vascular endothelial cells.
International panel updates treatment guidelines for HIV infection An evaluation of recent data has led to an update in the guidelines and recommendations for antiretroviral treatment of adult human immunodeficiency virus (HIV) infection, according to an article in the August 6 issue of JAMA, a theme issue on HIV/AIDS. More Protease Inhibitor Current Events and Protease Inhibitor News Articles
|
 |

|
Protease Inhibitors in AIDS Therapy (Infectious Disease and Therapy)
by Richard C. Ogden (Author), Charles Flexner (Author)
Agouron Pharmaceuticals, Inc., San Diego, CA. Reviews the impact of advances in recombinant DNA technology for understanding and treating HIV and AIDS. Highlights a variety of stories of pharmaceutical companies and biotechnology start-up firms. Reports on efforts to manage antiviral resistance in the clinic.
|

|
Charlie Rose with Forrest Sawyer; Ellen Barkin; Larry Kramer (January 18, 1995)
ABC News journalist Forrest Sawyer talks about his new program Day One, his ascent as a journalist, and the competitive world of network television. Then, Ellen Barkin discusses her new film Bad Company, co-starring Laurence Fishburne, her background, and her long and prolific career as an actor. Finally, Larry Kramer on AIDS and the American response to the epidemic.This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply.
|

|
Protease Inhibitor Kit - Pierce Halt Inhibitor Cocktails, Thermo Scientific - Model PI78410 - Each
by Thermo Scientific
Protease Inhibitor Kit - Pierce Halt Inhibitor Cocktails, Thermo Scientific - Model PI78410 - Each : The protease cocktail inhibits serine, cysteine, calpain proteases, and metalloproteases. It may be used with animal cells and tissues, bacteria, plants,
|

|
Viral Proteases and Antiviral Protease Inhibitor Therapy: Proteases in Biology and Disease
by Uwe Lendeckel (Editor), Nigel M. Hooper (Editor)
The 8th volume in the Proteases in Biology and Disease series focuses on the role of proteases in virus function and their potential as anti-viral targets. Viral infections are still difficult to threat and some remained life-threatening diseases in spite of antiviral drug research over decades. Proteases are still regarded as an Achilles’ heel of the pathogens and, thus, protease inhibitors may help to handle the known and the emerging viral threads. The book discusses viral proteases of the most important pathogenic viruses, responsible for severe diseases: AIDS, SARS, Hepatitis, Cytomegalovirus, T-cell lymphotropic virus, Picornavirus. This book focuses specifically on the viral proteases, crucial prerequisites for viral entry into cells and viral replication. Viral proteases...
|
|
|
Use of Protease Inhibitors may be Tied to Early MI. (HIV - Infected Patients).(heart attack): An article from: Internal Medicine News
by Bruce Jancin (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on January 1, 2002. The length of the article is 433 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Use of Protease Inhibitors may be Tied to Early MI. (HIV - Infected Patients).(heart attack) Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: January 1, 2002 Publisher: International Medical News Group Volume: 35 Issue: 1 Page: 12(1)
Distributed by Thomson...
|
|
|
Several agents under study for hepatitis C virus. (Oral Protease Inhibitor, Vaccine).: An article from: Family Practice News
by Patrice G.W. Norton (Author)
This digital document is an article from Family Practice News, published by International Medical News Group on July 1, 2003. The length of the article is 578 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Several agents under study for hepatitis C virus. (Oral Protease Inhibitor, Vaccine). Author: Patrice G.W. Norton Publication: Family Practice News (Magazine/Journal) Date: July 1, 2003 Publisher: International Medical News Group Volume: 33 Issue: 13 Page: 26(1)
Distributed by Thomson...
|
|
|
Pravastatin of some help in short trial: tough to curb PI-induced hyperlipidemia in HIV.(Infectious Diseases)(protease-inhibitor): An article from: Internal Medicine News
by Sherry Boschert (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on April 1, 2004. The length of the article is 581 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Pravastatin of some help in short trial: tough to curb PI-induced hyperlipidemia in HIV.(Infectious Diseases)(protease-inhibitor) Author: Sherry Boschert Publication: Internal Medicine News (Magazine/Journal) Date: April 1, 2004 Publisher: International Medical News Group Volume: 37 Issue: 7 Page: 56(1)
Distributed by Thomson...
|
|
|
Protease inhibitors: An entry from UXL's UXL Encyclopedia of Science
by UXL (Publisher)
This digital document is an article from UXL Encyclopedia of Science, brought to you by Gale®, a part of Cengage Learning, a world leader in e-research and educational publishing for libraries, schools and businesses. The length of the article is 915 words. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. This collection of entries covers major areas of science including: biology, genetics, microbiology, astronomy, chemistry, physics, engineering, technology, geology, weather, archaeology, psychology, mathematics, and medicine, and provides readers with a wide range of up-to-date, relevant, and accurate information.
|
|
|
Biological Functions of Proteases and Inhibitors
by Nobuhiko Katunuma (Author), Koichi Suzuki (Author), James Travis (Contributor)
Proteases are involved in various physiological regulatory mechanisms as well as in diverse pathological processes. Well understood examples are the blood clotting and complement pathways and the fibrinolytic system. Considerable interest has recently been focused on the involvement of proteases in tumour progression and viral infections. The importance of both the proteases and their inhibitors in human physiology and pathology are increasingly being recognized. This volume presents the latest findings in the field. Chapters are included on cell biological functions of membrane-bound proteases, the relationship between limited proteolysis and the processing of biologically active proteins, and tertiary structures of proteases and their protein inhibitors.
|
|
|
New protease inhibitor easy on lipids, tackles resistance. (Doesn't Raise Lipid Levels).(Brief Article): An article from: Internal Medicine News
by Timothy F. Kirn (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on May 1, 2002. The length of the article is 425 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: New protease inhibitor easy on lipids, tackles resistance. (Doesn't Raise Lipid Levels).(Brief Article) Author: Timothy F. Kirn Publication: Internal Medicine News (Magazine/Journal) Date: May 1, 2002 Publisher: International Medical News Group Volume: 35 Issue: 9 Page: 20(1)
Article Type: Brief Article
Distributed by Thomson...
|
|